Transcept Declares Special Dividend Of $12.79 Million And Additional Contingent Future Amounts In Connection With Its Merger With Paratek Pharmaceuticals

POINT RICHMOND, Calif., Oct. 14, 2014  -- Transcept Pharmaceuticals, Inc. (TSPT) announced today that its board of directors declared a special dividend, in connection with its merger with Paratek Pharmaceuticals, Inc., in the initial cash amount of $0.6674 per share on Transcept's common stock and the right to receive certain contingent cash amounts, in the future, on a pro rata basis, consisting of: (i) one hundred percent of any payments received by Transcept on or prior to the second anniversary of the closing date of the merger pursuant to the United States License and Collaboration Agreement, dated July 31, 2009, as amended November 1, 2011, by and between Transcept and Purdue Pharmaceutical Products L.P.,

Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection

Peer-Reviewed Data Show Peregrine Pharmaceuticals' PS-Targeting Antibody Bavituximab Exhibits Specific and Strong Binding to Ebola Virions and Ebola Virus-Infected Cells In Vitro; Data Supplement Published Scientific Literature Suggesting the Important Role of PS in Ebola Infection in Viral Entry and Immune Suppression During Infection

TUSTIN, CA--(Marketwired - Oct 15, 2014) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the publication of a peer-reviewed manuscript related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus (EBOV)-infected cells in vitro. These results will appear in the Vaccines and Therapies for Biodefense Agents special edition of the peer-reviewed Journal of Immunology Research in a manuscript titled: "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions."

GeneNews Adds Blood Test for Breast Cancer Prediction to Innovative Diagnostic Laboratory's Offering Menu

TORONTO, Oct. 14, 2014 -- GeneNews Limited (GEN.TO) ("GeneNews" or the "Company") today announced that it has in-licensed two biomarker assays - sphingotest(R) pro-NT and sphingotest(R) pro-ENK -- that aid physicians in identifying those females at highest risk for breast cancer in the general population. Both tests were developed by sphingotec GmbH, a Germany-based company best known for discovery and development of biomarker assays, which has recently expanded in the U.S.

GeneNews expects to add sphingotest(R) pro-NT to the menu of advanced cancer assays offered by its U.S. joint venture, Innovative Diagnostic Laboratory LLP ("IDL") in early 2015. The Company is also evaluating the potential expansion of IDL's testing menu in the area of breast cancer risk prediction through the addition of sphingotest(R) pro-ENK and other biomarker candidates.

Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects

GAITHERSBURG, Md., Oct. 14, 2014  -- Novavax, Inc. (NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy elderly subjects.

The trial is a randomized, observer-blinded, placebo-controlled Phase 2 study scheduled to enroll 1,600 elderly subjects (>60 years of age) at ten sites in the United States. The trial will evaluate the incidence of all respiratory illnesses due to RSV, including medically-attended respiratory illnesses due to RSV, and hospitalizations for respiratory illness due to RSV in community-living elderly adults who have been treated with placebo. The study will also evaluate the safety and immunogenicity of a 135ug dose of the RSV F Vaccine compared with placebo. The trial will also estimate the efficacy of the RSV F Vaccine in reducing the incidence of respiratory illnesses due to RSV.